Gene therapy for the leukodystrophies: From preclinical animal studies to clinical trials
- PMID: 39276676
- PMCID: PMC11418141
- DOI: 10.1016/j.neurot.2024.e00443
Gene therapy for the leukodystrophies: From preclinical animal studies to clinical trials
Abstract
Leukodystrophies are progressive single gene disorders affecting the white matter of the brain. Several gene therapy trials are in progress to address the urgent unmet need for this patient population. We performed a comprehensive literature review of all gene therapy clinical trials listed in www.clinicaltrials.gov through August 2024, and the relevant preclinical studies that enabled clinical translation. Of the approximately 50 leukodystrophies described to date, only eight have existing gene therapy clinical trials: metachromatic leukodystrophy, X-linked adrenoleukodystrophy, globoid cell leukodystrophy, Canavan disease, giant axonal neuropathy, GM2 gangliosidoses, Alexander disease and Pelizaeus-Merzbacher disease. What led to the emergence of gene therapy trials for these specific disorders? What preclinical data or disease context was enabling? For each of these eight disorders, we first describe its pathophysiology and clinical presentation. We discuss the impact of gene therapy delivery route, targeted cell type, delivery modality, dosage, and timing on therapeutic efficacy. We note that use of allogeneic hematopoietic stem cell transplantation in some leukodystrophies allowed for an accelerated path to clinic even in the absence of available animal models. In other leukodystrophies, small and large animal model studies enabled clinical translation of experimental gene therapies. Human clinical trials for the leukodystrophies include ex vivo lentiviral gene delivery, in vivo AAV-mediated gene delivery, and intrathecal antisense oligonucleotide approaches. We outline adverse events associated with each modality focusing specifically on genotoxicity and immunotoxicity. We review monitoring and management of events related to insertional mutagenesis and immune responses. The data presented in this review show that gene therapy, while promising, requires systematic monitoring to account for the precarious disease biology and the adverse events associated with new technology.
Keywords: Adeno-associated viral vector; Antisense oligonucleotide; Gene therapy; Lentiviral vector; Leukodystrophies.
Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest F.S. Eichler receives research support from NINDS (R01NS072446, R01NS082331, U54NS115052), institutional contracts from ASPA Therapeutics, Sanofi, Ionis, bluebird bio and Minoryx Therapeutics, and performs personal consulting for Sanofi, ASPA Therapeutics, UpToDate, Leal, Takeda, Atlas Venture, Acadia Pharmaceuticals and SwanBio Therapeutics.
Figures



Similar articles
-
An update on clinical, pathological, diagnostic, and therapeutic perspectives of childhood leukodystrophies.Expert Rev Neurother. 2020 Jan;20(1):65-84. doi: 10.1080/14737175.2020.1699060. Epub 2019 Dec 12. Expert Rev Neurother. 2020. PMID: 31829048 Review.
-
Recent Advancements in the Diagnosis and Treatment of Leukodystrophies.Semin Pediatr Neurol. 2021 Apr;37:100876. doi: 10.1016/j.spen.2021.100876. Epub 2021 Feb 10. Semin Pediatr Neurol. 2021. PMID: 33892849 Review.
-
Treatment of leukodystrophies: Advances and challenges.Eur J Paediatr Neurol. 2025 May;56:46-50. doi: 10.1016/j.ejpn.2025.03.016. Epub 2025 Apr 15. Eur J Paediatr Neurol. 2025. PMID: 40279833 Review.
-
The inherited leukodystrophies: a clinical overview.J Inherit Metab Dis. 1993;16(4):733-43. doi: 10.1007/BF00711905. J Inherit Metab Dis. 1993. PMID: 7692130 Review.
-
Leukodystrophy Imaging: Insights for Diagnostic Dilemmas.Med Sci (Basel). 2024 Jan 25;12(1):7. doi: 10.3390/medsci12010007. Med Sci (Basel). 2024. PMID: 38390857 Free PMC article. Review.
Cited by
-
A novel splice site variant in DEGS1 leads to aberrant splicing and loss of DEGS1 enzyme activity, a VUS resolved.medRxiv [Preprint]. 2025 Apr 11:2025.04.04.25325118. doi: 10.1101/2025.04.04.25325118. medRxiv. 2025. PMID: 40297416 Free PMC article. Preprint.
-
Gene therapy for neurologic disorders.Neurotherapeutics. 2024 Jul;21(4):e00453. doi: 10.1016/j.neurot.2024.e00453. Neurotherapeutics. 2024. PMID: 39318035 Free PMC article. No abstract available.
-
The neurological pathology of peroxisomal ACBD5 deficiency - lessons from patients and mouse models.Front Mol Neurosci. 2025 Jul 2;18:1602343. doi: 10.3389/fnmol.2025.1602343. eCollection 2025. Front Mol Neurosci. 2025. PMID: 40672445 Free PMC article. Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical